Log in

AVLN Avalyn Pharma Inc. NASDAQ · United States

Avalyn Pharma (AVLN) news AVLN IPO and offering news

Latest Avalyn Pharma news

  1. Financings

    Avalyn Pharma files for IPO, plans Nasdaq Global Market listing as AVLN

    Avalyn Pharma Inc. filed a Form S-1 on April 8, 2026. The cover leaves the share count and price range blank.

Questions about Avalyn Pharma

When did Avalyn Pharma go public?

Our latest story on this, dated Apr 30, 2026: "Avalyn Pharma prices IPO of 16,666,667 shares at $18.00". The story links the filing or release it is based on. Read the story.

Has Avalyn Pharma raised money recently?

Our latest story on this, dated Apr 30, 2026: "Avalyn Pharma prices IPO of 16,666,667 shares at $18.00". The story links the filing or release it is based on. Read the story.

What is the ticker symbol of Avalyn Pharma?

Avalyn Pharma Inc. trades under the ticker AVLN on NASDAQ.

Where is Avalyn Pharma listed?

Avalyn Pharma Inc. is listed on NASDAQ.

What is the SEC CIK of Avalyn Pharma?

The SEC Central Index Key (CIK) for Avalyn Pharma Inc. is 1540171. Its filings are on SEC EDGAR.

How many shares does Avalyn Pharma have outstanding?

44,333,095 shares as of 2026-08-31, per the cover page of its 10-Q filed 2026-08-12.

Which country or territory is Avalyn Pharma listed under?

Our directory records Avalyn Pharma Inc. under United States.

What does Avalyn Pharma do?

Our directory classifies Avalyn Pharma Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Avalyn Pharma?

The ISIN recorded for Avalyn Pharma Inc. is US05348Y1055.

Does aibio.space cover Avalyn Pharma?

aibio.space lists Avalyn Pharma Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Avalyn Pharma incorporated?

SEC records list its state or country of incorporation as DE.

What is the latest Avalyn Pharma (AVLN) stock news?

Our latest story on Avalyn Pharma, dated Apr 30, 2026: "Avalyn Pharma prices IPO of 16,666,667 shares at $18.00". The offering totals $300,000,006 before fees. The shares have been approved for listing on the Nasdaq Global Select Market as AVLN. Source.

How long will Avalyn Pharma's cash last?

From our story of Apr 30, 2026: The prospectus says the net proceeds, together with existing cash and the $15.0 million borrowed, will fund operating expenses and capital requirements into 2029. Source.

How much cash does Avalyn Pharma have?

From our story of Apr 30, 2026: At December 31, 2025, cash, cash equivalents and marketable securities totaled $138,359 thousand. Source.

Is Avalyn Pharma a smaller reporting company?

SEC records list Avalyn Pharma Inc.'s filer category as: <br>Emerging growth company.

Investor discussion: Avalyn Pharma

Members talk about Avalyn Pharma (AVLN). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Avalyn Pharma, newest first. Each line links the filing it comes from.

  1. Financings

    Filed a final prospectus for a securities offering. SEC Form 424B4. Source

  2. Financings

    Filed a registration statement for a share offering. SEC Form S-1. Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:AVLN on TradingView.

SEC filings and registration

SEC name
Avalyn Pharma Inc.
CIK
1540171
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
AVLN (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
<br>Emerging growth company
Business address
105 W FIRST ST., BOSTON, MA, 02127
Phone
(206) 707-0340
Shares outstanding
44,333,095 as of 2026-08-31 (10-Q filed 2026-08-12)
Former names
Genoa Pharmaceuticals, Inc.

Recent filings (8-K and 6-K are the company's own announcements)

  • 8-K filed 2026-09-16
  • 10-Q filed 2026-08-12
  • 8-K filed 2026-08-12
  • 8-K filed 2026-07-01
  • 8-K filed 2026-06-17
  • 10-Q filed 2026-06-03
  • 8-K filed 2026-06-03
  • 8-K filed 2026-05-01

Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

Listing details

Avalyn Pharma Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker AVLN, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Avalyn Pharma Inc.
Ticker
AVLN
Listing
NASDAQ
Country or territory
United States
Business scope
Pharmaceuticals: Major
ISIN
US05348Y1055
Last quote in directory
2026-10-21
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.